This combination of Gliclazide (40 mg), Metformin SR (500 mg), and Pioglitazone (15 mg) is used in the management of Type 2 Diabetes Mellitus, particularly in patients who need enhanced glycemic control beyond monotherapy or dual therapy. Gliclazide stimulates insulin secretion from pancreatic beta cells, Metformin SR helps reduce hepatic glucose production and improves insulin sensitivity, while Pioglitazone further enhances insulin action in peripheral tissues. Together, this triple-action therapy works synergistically to control fasting and post-meal blood glucose levels, improve insulin utilization, and help reduce the risk of long-term diabetic complications.
